Sun Pharma inches up after Taro begins share buyback offer

Image
Capital Market
Last Updated : Nov 26 2013 | 11:56 PM IST

Sun Pharmaceutical Industries rose 0.42% to Rs 583 at 14:37 IST on BSE after the company's unit Taro Pharmaceutical announced the start of a tender offer to buy back up to $200 million of its ordinary shares.

Meanwhile, the BSE Sensex was down 128.62 points, or 0.62%, to 20,476.46.

On BSE, 73,000 shares were traded in the counter compared with average volume of 1.44 lakh shares in the past one quarter.

The counter was quite volatile. The stock rose 1.80% at the day's a high of Rs 591 so far during the day. It fell 0.34% at the day's low of Rs 578.55 so far during the day.

The stock hit a 52-week high of Rs 650 on 10 October 2013. The stock hit a 52-week low of Rs 346.63 on 26 November 2012.

The stock had underperformed the market over the past one month till 25 November 2013, sliding 4.87% compared with the Sensex's 0.38% fall. The scrip had, however, outperformed the market in past one quarter, rising 14.45% as against Sensex's 11.26% rise.

The large-cap company has an equity capital of Rs 207.12 crore. Face value per share is Re 1.

If the offer is fully subscribed, the number of Taro Pharmaceutical Industries shares to be purchased in the offer represents approximately 4.6% to 5.3% of the unit's total outstanding shares.

Sun Pharma's stake in Taro will go up if the buyback be fully subscribed. As on 31 March 2013, Sun Pharmaceutical Industries held 65.89% stake in Taro Pharmaceutical Industries.

Sun Pharmaceutical Industries' consolidated net profit surged 325.63% to Rs 1362 crore on 58% increase in net sales to Rs 4192 crore in Q2 September 2013 over Q2 September 2012.

Sun Pharmaceutical Industries is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 26 2013 | 2:33 PM IST

Next Story